MedPath

Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)

Completed
Conditions
Advanced Prostate Cancer
Lower Urinary Tract Symptoms
Interventions
Registration Number
NCT01078545
Lead Sponsor
Abbott
Brief Summary

The purpose of the study is to determine the influence of GnRH (gonadotropin releasing hormone) analogue - Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine) administration on intensity of lower urinary tract symptoms (LUTS) in patients with diagnosed locally advanced and/or metastatic prostate cancer and LUTS.

Detailed Description

The remaining target is:

- to assess the intensity of LUTS in Polish and Ukrainian patients with locally advanced and metastatic prostate cancer, previously untreated with hormonal therapy

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
729
Inclusion Criteria
  • Age > 50 years
  • Locally advanced (T3-T4) and/or metastatic (N+/M+) hormone-sensitive prostate cancer, confirmed by histological examination
  • Presence of lower urinary tract symptoms (LUTS)-IPSS >0
  • Treatment with Lucrin® Depot is the routine therapy in the patient. The decision as to Lucrin® Depot choice will not be associated with patient's participation in the study, but will result from the best medical knowledge and practice.
  • Until inclusion into PMOS the patient has not been treated with GnRH analogue.
  • The patient, before inclusion into the study, has not been treated by surgery (radical prostatectomy).
Exclusion Criteria
  • Patients will not be included into the study if any contraindications to treatment with Lucrin® Depot exist, or if there are other treatment options which, according to the present medical knowledge, are potentially more beneficial for the patient.
  • Physician or patient can stop treatment at any moment, if any indications or reasons exist.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Adv. PCa patients with LUTS treated with GnRH analogueLeuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)Patients with advanced prostate cancer and lower urinary tract symptoms treated with GnRH analogue Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine)
Primary Outcome Measures
NameTimeMethod
The Change in the International Prostate Symptom Score (IPSS) From Baseline to Month 12. The IPSS Has a Range From 0 to 35.Baseline to 12 months

The International Prostate Symptom Score (IPSS) is used to assess the severity of lower urinary tract symptoms (LUTS) and to monitor disease progression. The IPSS is calculated from 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, and straining \[rated as 0 (not at all) to 5 (almost always)\], as well as how many times on average a participant has to get up to urinate at night (0=none to 5=5 times or more). The total score is classified as follows: 0 to 7 = mildly symptomatic; 8 to 19 = moderately symptomatic; and 20 to 35 = severely symptomatic.

Secondary Outcome Measures
NameTimeMethod
The Change in the International Prostate Symptom Score (IPSS) From Baseline to 3, 6, 9, and 12 Months.Baseline to 3, 6, 9, and 12 months.

The International Prostate Symptom Score (IPSS) is used to assess the severity of lower urinary tract symptoms (LUTS) and to monitor disease progression. The IPSS is calculated from 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, and straining \[rated as 0 (not at all) to 5 (almost always)\], as well as how many times on average a participant has to get up to urinate at night (0=none to 5=5 times or more). The total score is classified as follows: 0 to 7 = mildly symptomatic; 8 to 19 = moderately symptomatic; and 20 to 35 = severely symptomatic.

Percentage of Patients at Baseline With One of the Symptoms Connected With Prostate Cancer.Baseline

Percentage of participants at baseline with one of the following symptoms connected with prostate cancer: hematospermia (blood in the sperm), lower abdominal pain, urine incontinence, erectile dysfunction, crotch pain, anal pain or bleeding, lumbar/back pain, bone pain, spinal compression symptoms, peripheral lymph node enlargement, and lymphatic oedema of lower extremities. The intensity of each symptom was rated by the participant from 1 (minimum) to 7 (maximum). Zero indicates that the symptom was not present.

Reported Adverse Events/Serious Adverse EventsBaseline to 12 months

Adverse events (AEs) were collected during the course of the study from the first visit (Baseline) through the last visit (12 months). The number of participants experiencing a non-serious or serious adverse event or both types of events are summarized. See the Reported Adverse Event section for details.

Changes in the Intensity of Symptoms Connected With Prostate Cancer From Baseline to Month 3, 6, 9, and 12.Baseline to 3, 6, 9, and 12 months.

Changes in the intensity of the following symptoms connected with prostate cancer: hematospermia (blood in the sperm), lower abdominal pain, urine incontinence, erectile dysfunction, crotch pain, anal pain or bleeding, lumbar/back pain, bone pain, spinal compression symptoms, peripheral lymph node enlargement, and lymphatic oedema of lower extremities. The intensity of each symptom was rated by the participant from 1 (minimum) to 7 (maximum). Zero indicates that the symptom was not present.

Trial Locations

Locations (143)

Site Reference ID/Investigator# 30988

🇵🇱

Siemianowice Slaskie, Poland

Site Reference ID/Investigator# 31031

🇵🇱

Jastrzebie Zdroj, Poland

Site Reference ID/Investigator# 31076

🇵🇱

Belchatow, Poland

Site Reference ID/Investigator# 31002

🇵🇱

Bialystok, Poland

Site Reference ID/Investigator# 31004

🇵🇱

Elblag, Poland

Site Reference ID/Investigator# 31102

🇵🇱

Kluczbork, Poland

Site Reference ID/Investigator# 31030

🇵🇱

Bialystok, Poland

Site Reference ID/Investigator# 31048

🇵🇱

Bialystok, Poland

Site Reference ID/Investigator# 31028

🇵🇱

Bydgoszcz, Poland

Site Reference ID/Investigator# 31083

🇵🇱

Bobrowniki, Poland

Site Reference ID/Investigator# 31006

🇵🇱

Bytom, Poland

Site Reference ID/Investigator# 31090

🇵🇱

Elblag, Poland

Site Reference ID/Investigator# 31044

🇵🇱

Elk, Poland

Site Reference ID/Investigator# 30994

🇵🇱

Florentynow, Poland

Site Reference ID/Investigator# 31055

🇵🇱

Kielce, Poland

Site Reference ID/Investigator# 31020

🇵🇱

Konin, Poland

Site Reference ID/Investigator# 31087

🇵🇱

Krakow, Poland

Site Reference ID/Investigator# 31080

🇵🇱

Olsztyn, Poland

Site Reference ID/Investigator# 30989

🇵🇱

Opole, Poland

Site Reference ID/Investigator# 31049

🇵🇱

Lublin, Poland

Site Reference ID/Investigator# 31013

🇵🇱

Plock, Poland

Site Reference ID/Investigator# 33278

🇵🇱

Lublin, Poland

Site Reference ID/Investigator# 30978

🇵🇱

Opole, Poland

Site Reference ID/Investigator# 31001

🇵🇱

Milcz, Poland

Site Reference ID/Investigator# 31009

🇵🇱

Poddebice, Poland

Site Reference ID/Investigator# 31045

🇵🇱

Poznan, Poland

Site Reference ID/Investigator# 30979

🇵🇱

Puszczykowo, Poland

Site Reference ID/Investigator# 31022

🇵🇱

Pyskowice, Poland

Site Reference ID/Investigator# 31092

🇵🇱

Suwalki, Poland

Site Reference ID/Investigator# 31071

🇵🇱

Tarnow, Poland

Site Reference ID/Investigator# 31024

🇵🇱

Siedlce, Poland

Site Reference ID/Investigator# 31078

🇵🇱

Warsaw, Poland

Site Reference ID/Investigator# 31062

🇵🇱

Wroclaw, Poland

Site Reference ID/Investigator# 31070

🇵🇱

Wroclaw, Poland

Site Reference ID/Investigator# 31084

🇵🇱

Suwalki, Poland

Site Reference ID/Investigator# 31091

🇵🇱

Tarnow, Poland

Site Reference ID/Investigator# 30980

🇵🇱

Tomaszow Mazowiecki, Poland

Site Reference ID/Investigator# 31059

🇵🇱

Torun, Poland

Site Reference ID/Investigator# 31105

🇵🇱

Warsaw, Poland

Site Reference ID/Investigator# 30987

🇵🇱

Turek, Poland

Site Reference ID/Investigator# 31093

🇵🇱

Warsaw, Poland

Site Reference ID/Investigator# 31038

🇵🇱

Wroclaw, Poland

Site Reference ID/Investigator# 31077

🇵🇱

Wroclaw, Poland

Site Reference ID/Investigator# 31110

🇺🇦

Kiev, Ukraine

Site Reference ID/Investigator# 31072

🇵🇱

Wroclaw, Poland

Site Reference ID/Investigator# 30981

🇵🇱

Zory, Poland

Site Reference ID/Investigator# 31108

🇺🇦

Dnepropetrovsk, Ukraine

Site Reference ID/Investigator# 31111

🇺🇦

Donetsk, Ukraine

Site Reference ID/Investigator# 31073

🇵🇱

Zlotniki, Poland

Site Reference ID/Investigator# 31109

🇺🇦

Dnepropetrovsk, Ukraine

Site Reference ID/Investigator# 31112

🇺🇦

Kharkov, Ukraine

Site Reference ID/Investigator# 31209

🇺🇦

Kiev, Ukraine

Site Reference ID/Investigator# 31107

🇺🇦

Kiev, Ukraine

Site Reference ID/Investigator# 21103

🇺🇦

Kiev, Ukraine

Site Reference ID/Investigator# 31115

🇺🇦

Simferopol', Ukraine

Site Reference ID/Investigator# 30977

🇵🇱

Bialystok, Poland

Site Reference ID/Investigator# 31007

🇵🇱

Ciechanow, Poland

Site Reference ID/Investigator# 30976

🇵🇱

Brwinow, Poland

Site Reference ID/Investigator# 31014

🇵🇱

Bytom, Poland

Site Reference ID/Investigator# 31018

🇵🇱

Bytom, Poland

Site Reference ID/Investigator# 31101

🇵🇱

Gdansk, Poland

Site Reference ID/Investigator# 31032

🇵🇱

Jankowo, Poland

Site Reference ID/Investigator# 31065

🇵🇱

Jastrzebie Zdroj, Poland

Site Reference ID/Investigator# 31036

🇵🇱

Katowice, Poland

Site Reference ID/Investigator# 31039

🇵🇱

Lomza, Poland

Site Reference ID/Investigator# 31075

🇵🇱

Opole, Poland

Site Reference ID/Investigator# 31042

🇵🇱

Ostrow Wielkopolski, Poland

Site Reference ID/Investigator# 31098

🇵🇱

Zabrze, Poland

Site Reference ID/Investigator# 31088

🇵🇱

Poznan, Poland

Site Reference ID/Investigator# 31058

🇵🇱

Poznan, Poland

Site Reference ID/Investigator# 31064

🇵🇱

Pulawy, Poland

Site Reference ID/Investigator# 31005

🇵🇱

Pulawy, Poland

Site Reference ID/Investigator# 31041

🇵🇱

Rzeszow, Poland

Site Reference ID/Investigator# 31015

🇵🇱

Sosnowiec, Poland

Site Reference ID/Investigator# 30983

🇵🇱

Starachowice, Poland

Site Reference ID/Investigator# 33277

🇵🇱

Suwałki, Poland

Site Reference ID/Investigator# 31003

🇵🇱

Swietochlowice, Poland

Site Reference ID/Investigator# 31035

🇵🇱

Szczecin, Poland

Site Reference ID/Investigator# 31027

🇵🇱

Wroclaw, Poland

Site Reference ID/Investigator# 31094

🇵🇱

Warsaw, Poland

Site Reference ID/Investigator# 30996

🇵🇱

Zamosc, Poland

Site Reference ID/Investigator# 31054

🇵🇱

Jelenia Gora, Poland

Site Reference ID/Investigator# 9803

🇵🇱

Gdansk, Poland

Site Reference ID/Investigator# 31057

🇵🇱

Gdansk, Poland

Site Reference ID/Investigator# 31023

🇵🇱

Inowroclaw, Poland

Site Reference ID/Investigator# 31067

🇵🇱

Jaroslawiec, Poland

Site Reference ID/Investigator# 31097

🇵🇱

Gdansk, Poland

Site Reference ID/Investigator# 30984

🇵🇱

Gliwice, Poland

Site Reference ID/Investigator# 31051

🇵🇱

Imielnik Stary, Poland

Site Reference ID/Investigator# 31074

🇵🇱

Inowroclaw, Poland

Site Reference ID/Investigator# 30995

🇵🇱

Jastkow, Poland

Site Reference ID/Investigator# 30997

🇵🇱

Katowice, Poland

Site Reference ID/Investigator# 30999

🇵🇱

Kielce, Poland

Site Reference ID/Investigator# 31068

🇵🇱

Kolbudy, Poland

Site Reference ID/Investigator# 31011

🇵🇱

Krakow, Poland

Site Reference ID/Investigator# 31019

🇵🇱

Krakow, Poland

Site Reference ID/Investigator# 31050

🇵🇱

Krakow, Poland

Site Reference ID/Investigator# 31043

🇵🇱

Krakow, Poland

Site Reference ID/Investigator# 31047

🇵🇱

Lodz, Poland

Site Reference ID/Investigator# 31025

🇵🇱

Krakow, Poland

Site Reference ID/Investigator# 31061

🇵🇱

Krakow, Poland

Site Reference ID/Investigator# 31029

🇵🇱

Kurow, Poland

Site Reference ID/Investigator# 31010

🇵🇱

Lask, Poland

Site Reference ID/Investigator# 31096

🇵🇱

Lazy, Poland

Site Reference ID/Investigator# 31053

🇵🇱

Krakow, Poland

Site Reference ID/Investigator# 31012

🇵🇱

Legnica, Poland

Site Reference ID/Investigator# 31040

🇵🇱

Leszno, Poland

Site Reference ID/Investigator# 31086

🇵🇱

Lodz, Poland

Site Reference ID/Investigator# 31082

🇵🇱

Lidzbark Warminski, Poland

Site Reference ID/Investigator# 31052

🇵🇱

Lodz, Poland

Site Reference ID/Investigator# 31060

🇵🇱

Lodz, Poland

Site Reference ID/Investigator# 31089

🇵🇱

Lodz, Poland

Site Reference ID/Investigator# 31100

🇵🇱

Lublin, Poland

Site Reference ID/Investigator# 31104

🇵🇱

Lublin, Poland

Site Reference ID/Investigator# 31056

🇵🇱

Michalowice Osiedle, Poland

Site Reference ID/Investigator# 31103

🇵🇱

Lublin, Poland

Site Reference ID/Investigator# 30998

🇵🇱

Lublin, Poland

Site Reference ID/Investigator# 30993

🇵🇱

Oborniki Slaskie, Poland

Site Reference ID/Investigator# 31033

🇵🇱

Opole, Poland

Site Reference ID/Investigator# 30985

🇵🇱

Poznan, Poland

Site Reference ID/Investigator# 31085

🇵🇱

Nysa, Poland

Site Reference ID/Investigator# 30974

🇵🇱

Olsztyn, Poland

Site Reference ID/Investigator# 30982

🇵🇱

Opole, Poland

Site Reference ID/Investigator# 31000

🇵🇱

Piotrkow Trybunalski, Poland

Site Reference ID/Investigator# 31069

🇵🇱

Pila, Poland

Site Reference ID/Investigator# 31021

🇵🇱

Poznan, Poland

Site Reference ID/Investigator# 31034

🇵🇱

Poznan, Poland

Site Reference ID/Investigator# 31016

🇵🇱

Radlin, Poland

Site Reference ID/Investigator# 31099

🇵🇱

Radom, Poland

Site Reference ID/Investigator# 31063

🇵🇱

Sieradz, Poland

Site Reference ID/Investigator# 30992

🇵🇱

Szczecin, Poland

Site Reference ID/Investigator# 31008

🇵🇱

Swarzedz, Poland

Site Reference ID/Investigator# 30975

🇵🇱

Szczecin, Poland

Site Reference ID/Investigator# 31046

🇵🇱

Szczecin, Poland

Site Reference ID/Investigator# 31079

🇵🇱

Tarnowskie Gory, Poland

Site Reference ID/Investigator# 31066

🇵🇱

Warsaw, Poland

Site Reference ID/Investigator# 31106

🇵🇱

Warsaw, Poland

Site Reference ID/Investigator# 31037

🇵🇱

Warsaw, Poland

Site Reference ID/Investigator# 31081

🇵🇱

Warsaw, Poland

Site Reference ID/Investigator# 31095

🇵🇱

Warsaw, Poland

Site Reference ID/Investigator# 30986

🇵🇱

Wieliczka, Poland

Site Reference ID/Investigator# 31113

🇺🇦

Kharkov, Ukraine

Site Reference ID/Investigator# 31114

🇺🇦

Kharkov, Ukraine

© Copyright 2025. All Rights Reserved by MedPath